Thank you.
Drugs have been described as products that are not necessarily the same as other consumer products, when it comes to ensuring patient safety and therapies.
Mr. Poston, when you spoke about the need for Health Canada to play a broader and more proactive role in these types of situations, you said you were in favour of a voluntary system for manufacturers to report conditions that pose a risk.
And yet, when manufacturers do not necessarily follow the rules and fail to report risks regarding their drugs, what do you think Health Canada should do?